Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Osteoporosis in osteogenesis imperfecta].

Taichi Kitaoka1, Takehisa Yamamoto

  • 1Department of Pediatrics, Minoh City Hospital.

Clinical Calcium
|March 19, 2005
PubMed
Summary

Osteogenesis imperfecta (OI) is a genetic bone disorder with varying severity. Pamidronate therapy helps children with severe OI, but optimal treatment duration and adult/post-menopausal therapies require further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiological survey of bovine leukemia virus in beef cattle in the Tohoku region of Japan.

The Journal of veterinary medical science·2026
Same author

Evaluation of the Johne's disease surveillance program in dairy herds in Hokkaido, Japan, using a stochastic individual-based simulation model.

The Journal of veterinary medical science·2026
Same author

Correction to: Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial.

Calcified tissue international·2026
Same author

The 2025 outbreak of equine influenza among draft horses at Obihiro Racecourse, Hokkaido, Japan.

The Journal of veterinary medical science·2026
Same author

Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial.

Calcified tissue international·2025
Same author

Detection of Long-Distance Transmission Events During the CSF Epidemic in Japan Using Whole-Genome-Sequence Data.

Transboundary and emerging diseases·2025

Area of Science:

  • Genetics
  • Bone Metabolism
  • Pharmacology

Context:

  • Osteogenesis imperfecta (OI) is a heterogeneous genetic disorder characterized by bone fragility.
  • Clinical presentation of OI ranges from mild to lethal, impacting bone mineral density (BMD) and fracture risk.
  • Current therapeutic strategies for OI, particularly pamidronate infusion, show efficacy in severe pediatric cases but raise questions regarding treatment cessation and long-term management.

Purpose:

  • To review the current understanding of Osteogenesis imperfecta (OI) and its therapeutic landscape.
  • To highlight the challenges in managing OI, including determining optimal pamidronate therapy duration in children.
  • To identify unmet needs in the treatment of adult and post-menopausal OI patients.

Summary:

  • Osteogenesis imperfecta (OI) encompasses a spectrum of genetic bone disorders with diverse clinical manifestations.
  • While pamidronate infusion is effective for severe pediatric OI, the optimal timing for therapy discontinuation to ensure proper bone fracture healing remains unclear.
  • Effective treatment strategies for adult and post-menopausal individuals with OI are yet to be fully established.

Impact:

  • This review underscores the need for evidence-based guidelines on pamidronate therapy cessation in pediatric OI.
  • It emphasizes the critical requirement for further research to define optimal therapeutic approaches for adult and post-menopausal OI patients.
  • The findings aim to guide future clinical practice and research endeavors in managing this complex genetic condition.

Related Experiment Videos